Status: Recruiting
GKL-006 Injection Plus TACE Versus TACE Alone in Patients With Unresectable Hepatocellular Carcinoma
This is a multicenter, randomized, open-label, controlled Phase 2 study in patients with unresectable hepatocellular carcinoma (uHCC). The purpose of this study is to compare the efficacy and safety of GKL-006 Injection in combination with transarterial chemoembolization (TACE) versus TACE alone.
Participants needed: 48
Trial details
Phase: Phase 2Age: 18-80Biological sex: AllType: InterventionalSponsor: Beijing Gene Key Life Technology Co., LtdUpdated: Aug 17, 2026Locations: 7
Eligibility criteria
Voluntarily participates in the study and provides written informed consent. [+7]
Has a known allergy to the investigational product or related components, includ... [+6]